Insight into systematic development of ALK (anaplastic lymphoma kinase) inhibitors towards NSCLC treatment

• Päätekijät: Vivek Yadav (Tekijä), Jurnal Reang (Tekijä), Vinita (Tekijä), Prabodh Chander Sharma (Tekijä), Kalicharan Sharma (Tekijä), Deepak Kumar (Tekijä), Rajiv Kumar Tonk (Tekijä)
• Aineistotyyppi: Kirja
• Julkaistu: Elsevier, 2024-04-01T00:00:00Z.
• Aiheet: article
• Linkit: Connect to this object online.

Among cancer-related disorders, lung carcinoma is one of the leading causes of mortality. Anaplastic lymphoma kinase (ALK) belongs to tyrosine kinase receptor family and exhibits similar characteristics to insulin type receptors. The treatment of advanced non-small cell lung cancer (NSCLC) associate...